---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-002876"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:12:19.510918+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance

## Summary
- Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).
- GAAP diluted EPS from continuing ops -$0.11 (vs -$0.16); total diluted EPS -$0.34. Non-GAAP EPS $0.09 (vs $0.12).
- Gross margin 42.9% (down 380bps) on lost leverage & rework costs; operating margin -4.9%.
- Adjusted EBITDA $13M, margin 8.5% (down 230bps). Board authorized $250M share repurchase program through Dec 2028.
- Definitive agreement to sell B Medical Systems for $63M; close expected by March 31, 2026. FY2026 guidance reaffirmed: organic rev growth 3-5%, ~300bps adj EBITDA margin expansion.

## SEC filing metadata
- accession: 0001437749-26-002876
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000143774926002876/0001437749-26-002876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000143774926002876/azta20251120_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-002876
- JSON: https://secwatch.observer/filing/0001437749-26-002876.json
- Plain text: https://secwatch.observer/filing/0001437749-26-002876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.